Literature DB >> 2074515

Voided urine flow cytometry in screening high-risk patients for the presence of bladder cancer.

D K Hermansen1, R A Badalament, P R Bretton, M Kimmel, C M Aswad, W F Whitmore, M R Melamed.   

Abstract

Fifty-nine patients with a history of bladder cancer were evaluated with three serially voided urines for flow cytometry and cytology within the 24 hours preceding cystoscopy, bladder wash, and biopsy. Evaluation of the 32 patients with biopsy proven cancer revealed that for one, two, and three voided urine specimens, the sensitivity of flow cytometry in detecting bladder cancer was 29%, 35%, and 41%, respectively, whereas the sensitivity of voided urine cytology was 44%, 53%, and 57%, respectively. Bladder wash flow cytometry had a sensitivity of 76%. Interpretation of the voided urine flow cytometry was based on a control group of 80 volunteers with negative voided urine cytology. The control group demonstrated that a minimum of 1500 analyzable cells was necessary for a reliable histogram. Considering all 59 patients, voided urine flow cytometry, bladder wash flow cytometry, and voided urine cytology were acceptable for analysis in 53%, 93%, and 100% of the specimens, respectively. Voided urine specimens appear less suitable than bladder irrigation specimens for evaluation by flow cytometry. Voided urine flow cytometry is less sensitive in detecting bladder cancer than voided urinary cytology or bladder wash flow cytometry and is not effective for use as a bladder cancer screening test.

Entities:  

Mesh:

Year:  1990        PMID: 2074515     DOI: 10.1097/00043764-199009000-00028

Source DB:  PubMed          Journal:  J Occup Med        ISSN: 0096-1736


  2 in total

1.  Quantitative phase imaging to improve the diagnostic accuracy of urine cytology.

Authors:  Hoa V Pham; Liron Pantanowitz; Yang Liu
Journal:  Cancer Cytopathol       Date:  2016-05-13       Impact factor: 5.284

2.  Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria.

Authors:  Kogenta Nakamura; Ali Kasraeian; Kenneth A Iczkowski; Myron Chang; John Pendleton; Satoshi Anai; Charles J Rosser
Journal:  BMC Urol       Date:  2009-09-10       Impact factor: 2.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.